AI Chat Paper
Discover the SciOpen Platform and Achieve Your Research Goals with Ease.
Search articles, authors, keywords, DOl and etc.
{{expandStatus?'Exit ':''}}Advanced Search
Nanotechnology has become integral in the improvement of methodology used to identify and treat various cancers. Nanoparticles (NPs) exhibit unique features that enhance sensitivity and selectivity and subsequently reduce the time required to detect early-stage cancer through biomarkers. NPs improve the therapeutic efficiency of anticancer agents when compared with conventional methods, such as chemotherapy, and thereby eliminate toxicity and side effects, which helps improve the stability, solubility, half-life, and tumor aggregation of an anticancer drug. This also helps expedite the treatment cycle by enabling a real-time assessment, quickly circumventing various biological barriers, improving vectorization and delivery, overcoming drug resistance, and developing various paths for the manufacturing of new synthetic vaccines. Nanomedicine has usually involved studies on solid-state cancers because it can increase the cell permeability and retention effect experienced within the tumor areas to improve regional accumulation and efficacy. Nanomedicine for leukemia and lymphoma is addressed differently from solid-state cancers because of the absence of the enhanced permeability and retention effect.
Nevertheless, nanomedicine has enabled the development of various modern innovative techniques for simple and noninvasive procedures for prior analysis of cancers with subsequent diffuse tumor treatment. In this assessment, we consider various unique constructs on NPs that can predominantly enhance therapeutic treatment over diffused tumors by increasing control, from preclinical testing to medicinal trials. Nanotechnology combines nanodiagnostics, nanotherapeutics, and nanotheranostics for improved imaging and diagnoses of early stage cancers. Furthermore, the primacy of nanoplatforms has been discussed for an invaluable position in this blended method. There are many types of NPs, such as organic, inorganic, and hybrid NPs. The minute size of NPs makes them ideal for intracellular uptake, and the large surface area ratio allows functional interactions with various compounds. This review also covers targeting cancerous cells via inducing lysosomal autophagy using gold NPs.
D. Hu, A. Shilatifard. Epigenetics of hematopoiesis and hematological malignancies. Genes &Development, 2016, 30(18): 2021−2041. https://doi.org/10.1101/gad.284109.116
M. Cazzola. Introduction to a review series: The 2016 revision of the WHO classification of tumors of hematopoietic and lymphoid tissues. Blood, 2016, 127(20): 2361−2364. https://doi.org/10.1182/blood-2016-03-657379
C.L. Freeman, J.G. Gribben. Immunotherapy in chronic lymphocytic leukaemia (CLL). Current Hematologic Malignancy Reports, 2016, 11(1): 29−36. https://doi.org/10.1007/s11899-015-0295-9
J. Mondal, A.K. Panigrahi, A.R. Khuda-Bukhsh. Conventional chemotherapy: Problems and scope for combined therapies with certain herbal products and dietary supplements. Austin Journal of Molecular and Cellular Biology, 2014, 1(1): 10.
J.K. Patra, G. Das, L.F. Fraceto, et al. Nano based drug delivery systems: Recent developments and future prospects. Journal of Nanobiotechnology, 2018, 16(1): 71. https://doi.org/10.1186/s12951-018-0392-8
R. Vinhas, M. Cordeiro, F. Carlos, et al. Gold nanoparticle-based theranostics: Disease diagnostics and treatment using a single nanomaterial. Nanobiosensors in Disease Diagnosis, 2015, 4: 11−23. https://doi.org/10.2147/NDD.S60285
S. Hasan. A review on nanoparticles: Their synthesis and types. Research Journal of Recent Sciences, 2015, 4: 1−3.
A.S. Tatar, T. Nagy-Simon, C. Tomuleasa, et al. Nanomedicine approaches in acute lymphoblastic leukemia. Journal of Controlled Release, 2016, 238: 123−138. https://doi.org/10.1016/j.jconrel.2016.07.035
A.K. Biswas, M.R. Islam, Z.S. Choudhury, et al. Nanotechnology based approaches in cancer therapeutics. Advances in Natural Sciences:Nanoscience and Nanotechnology, 2014, 5(4): 043001. https://doi.org/10.1088/2043-6262/5/4/043001
S. Gavas, S. Quazi, T.M. Karpiński. Nanoparticles for cancer therapy: Current progress and challenges. Nanoscale Research Letters, 2021, 16(1): 1−21. https://doi.org/10.1186/s11671-021-03628-6
Y.H. Yao, Y.X. Zhou, L.H. Liu, et al. Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. Frontiers in Molecular Bioscience, 2020, 7: 193. https://doi.org/10.3389/fmolb.2020.00193
S. Tinkle, S.E. McNeil, S. Mühlebach, et al. Nanomedicines: Addressing the scientific and regulatory gap. Annals of the New York Academy of Sciences, 2014, 1313(1): 35−56. https://doi.org/10.1111/nyas.12403
R. Mendes, B. Carreira, P.V. Baptista, et al. Non-small cell lung cancer biomarkers and targeted therapy - two faces of the same coin fostered by nanotechnology. Expert Review of Precision Medicine and Drug Development, 2016, 1(2): 155−168. https://doi.org/10.1080/23808993.2016.1159914
S.R. Croy, G.S. Kwon. Polymeric micelles for drug delivery. Current Pharmaceutical Design, 2006, 12(36): 4669−4684. https://doi.org/10.2174/138161206779026245
V. Krishnan, X. Xu, D. Kelly, et al. CD19-targeted nanodelivery of doxorubicin enhances therapeutic efficacy in B-cell acute lymphoblastic leukemia. Molecular Pharmaceutics, 2015, 12(6): 2101−2111. https://doi.org/10.1021/acs.molpharmaceut.5b00071
M.J. Liu, J.M.J. Fréchet. Designing dendrimers for drug delivery. Pharmaceutical Science &Technology Today, 1999, 2(10): 393−401. https://doi.org/10.1016/S1461-5347(99)00203-5
J.L. Arias. Liposomes in drug delivery: A patent review (2007–present). Expert Opinion on Therapeutic Patents, 2013, 23(11): 1399−1414. https://doi.org/10.1517/13543776.2013.828035
M. Alavi, M. Hamidi. Passive and active targeting in cancer therapy by liposomes and lipid nanoparticles. Drug Metabolism and Personalized Therapy, 2019, 34(1): 20180032. https://doi.org/10.1515/dmpt-2018-0032
T. Moodley, M. Singh. Current stimuli-responsive mesoporous silica nanoparticles for cancer therapy. Pharmaceutics, 2021, 13(1): 71. https://doi.org/10.3390/pharmaceutics13010071
A. Nel, T. Xia, L. Mädler, et al. Toxic potential of materials at the nanolevel. Science, 2006, 311(5761): 622−627. https://doi.org/10.1126/science.1114397
R. Shukla, V. Bansal, M. Chaudhary, et al. Biocompatibility of gold nanoparticles and their endocytotic fate inside the cellular compartment: A microscopic overview. Langmuir, 2005, 21(23): 10644−10654. https://doi.org/10.1021/la0513712
M. Hameed, S. Panicker, S. H. Abdallah, et al. Protein-coated aryl modified gold nanoparticles for cellular uptake study by osteosarcoma cancer cells. Langmuir, 2020, 36(40): 11765−11775. https://doi.org/10.1021/acs.langmuir.0c01443
Y. Wu, M.R.K. Ali, K.C. Chen, et al. Gold nanoparticles in biological optical imaging. Nano Today, 2019, 24: 120−140. https://doi.org/10.1016/j.nantod.2018.12.006
C. Ungureanu, R. Kroes, W. Petersen, et al. Light interactions with gold nanorods and cells: Implications for photothermal nanotherapeutics. Nano Letters, 2011, 11(5): 1887−1894. https://doi.org/10.1021/nl103884b
S. Jain, D.G. Hirst, J.M. O'Sullivan. Gold nanoparticles as novel agents for cancer therapy. Computational Intelligence and Neuroscience, 2012, 85(1010): 101−113. https://doi.org/10.1259/bjr/59448833
Y. Feng, K. Yang, H.-H. Sun, et al. Value of preoperative gastroscopic carbon nanoparticles labeling in patients undergoing laparoscopic radical gastric cancer surgery. Surgical Oncology, 2021, 38: 101628. https://doi.org/10.1016/j.suronc.2021.101628
C.J. Hu, M.Z. Xu, R.J. Qin, et al. Wogonin induces apoptosis and endoplasmic reticulum stress in HL-60 leukemia cells through inhibition of the PI3K-AKT signaling pathway. Oncology Reports, 2015, 33(6): 3146−3154. https://doi.org/10.3892/or.2015.3896
R.A. Revia, M.Q. Zhang. Magnetite nanoparticles for cancer diagnosis, treatment, and treatment monitoring: Recent advances. Materials Today, 2016, 19(3): 157−168. https://doi.org/10.1016/j.mattod.2015.08.022
K. Hayashi, M. Nakamura, H. Miki, et al. Magnetically responsive smart nanoparticles for cancer treatment with a combination of magnetic hyperthermia and remote-control drug release. Theranostics, 2014, 4(8): 834−844. https://doi.org/10.7150/thno.9199
H.M. Chen, W.Z. Zhang, G.Z. Zhu, et al. Rethinking cancer nanotheranostics. Nature Reviews Materials, 2017, 2: 17024. https://doi.org/10.1038/natrevmats.2017.24
T. Lammers, F. Kiessling, W.E. Hennink, et al. Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress. Journal of Controlled Release, 2012, 161(2): 175−187. https://doi.org/10.1016/j.jconrel.2011.09.063
L. Levy, C. Tower, A. Thorburn. Targeting autophagy in cancer. Nature Reviews Cancer, 2017, 17(9): 528−542. https://doi.org/10.1038/nrc.2017.53
X.J. Jiang, M. Overholtzer, C.B. Thompson. Autophagy in cellular metabolism and cancer. Journal of Clinical Investigation, 2015, 125(1): 47−54. https://doi.org/10.1172/JCI73942
Y.S. Chen, Y.C. Hung, I. Liau, et al. Assessment of the in vivo toxicity of gold nanoparticles. Nanoscale Research Letters, 2009, 4(8): 858−864. https://doi.org/10.1007/s11671-009-9334-6
This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY) (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
京公网安备11010802044758号